Myriad Genetics launches Prolaris + AI, the first prostate cancer test to combine genomics and digital pathology artificial intelligence

[출처/시간] Briefing.com - 4:18 PM ET, 05/26/2026

SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test at the end of this month. Prolaris will be the first and only prostate cancer biomarker test to unite clinical-pathological features, an independent molecular score, and independent AI-powered digital pathology technology.1-4 This combination helps identify if a patient is safe for active surveillance and how refinement of AS intensity can be personalized.4-8 This new paradigm in patient care builds upon technology from PATHOMIQ AI, a digital pathology AI platform company. The Prolaris + AI test is the only test where AS metrics on patient results were built on studies with previously diagnosed, untreated patient cohorts.1-4 The Prolaris + AI test will continue to help doctors identify patients who are safe for single-modal treatment.9-10Click here for full release.